Peter K. H. Lau

1.4k total citations
41 papers, 675 citations indexed

About

Peter K. H. Lau is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Peter K. H. Lau has authored 41 papers receiving a total of 675 indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Oncology, 13 papers in Molecular Biology and 10 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Peter K. H. Lau's work include Cancer Immunotherapy and Biomarkers (12 papers), CAR-T cell therapy research (10 papers) and Melanoma and MAPK Pathways (9 papers). Peter K. H. Lau is often cited by papers focused on Cancer Immunotherapy and Biomarkers (12 papers), CAR-T cell therapy research (10 papers) and Melanoma and MAPK Pathways (9 papers). Peter K. H. Lau collaborates with scholars based in Australia, United States and United Kingdom. Peter K. H. Lau's co-authors include Grant A. McArthur, Sherene Loi, Amanda J. Oliver, Phillip K. Darcy, Clare Y. Slaney, Michael H. Kershaw, Jasna Aleksova, Georgia Soldatos, Richard H. Aster and Shahneen Sandhu and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Scientific Reports.

In The Last Decade

Peter K. H. Lau

39 papers receiving 655 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Peter K. H. Lau Australia 14 374 157 154 151 67 41 675
Taner Babacan Türkiye 15 409 1.1× 65 0.4× 181 1.2× 136 0.9× 70 1.0× 52 788
Tian Tian China 19 279 0.7× 128 0.8× 229 1.5× 242 1.6× 53 0.8× 70 892
Lynn O’Donnell United States 12 322 0.9× 187 1.2× 187 1.2× 65 0.4× 167 2.5× 30 788
Lisa Argnani Italy 21 537 1.4× 261 1.7× 127 0.8× 200 1.3× 79 1.2× 120 1.4k
Shu‐Fang Hsu Schmitz Switzerland 16 421 1.1× 82 0.5× 109 0.7× 185 1.2× 36 0.5× 34 980
Émmanuelle Vigarios France 12 402 1.1× 97 0.6× 119 0.8× 96 0.6× 38 0.6× 39 729
M. Bauer Germany 12 130 0.3× 103 0.7× 262 1.7× 86 0.6× 64 1.0× 31 581
Xiaohan Shi China 15 243 0.6× 100 0.6× 178 1.2× 123 0.8× 28 0.4× 44 701
Theo van den Broek Netherlands 12 106 0.3× 331 2.1× 125 0.8× 157 1.0× 54 0.8× 27 734
Jacob Garcia United States 18 867 2.3× 86 0.5× 145 0.9× 81 0.5× 60 0.9× 47 1.0k

Countries citing papers authored by Peter K. H. Lau

Since Specialization
Citations

This map shows the geographic impact of Peter K. H. Lau's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter K. H. Lau with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter K. H. Lau more than expected).

Fields of papers citing papers by Peter K. H. Lau

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter K. H. Lau. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter K. H. Lau. The network helps show where Peter K. H. Lau may publish in the future.

Co-authorship network of co-authors of Peter K. H. Lau

This figure shows the co-authorship network connecting the top 25 collaborators of Peter K. H. Lau. A scholar is included among the top collaborators of Peter K. H. Lau based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter K. H. Lau. Peter K. H. Lau is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Hamid, Omid, Juanita Lopez, Daniel G. Olson, et al.. (2024). Phase 1 safety and efficacy of IMC-F106C, a PRAME × CD3 ImmTAC bispecific, in post-checkpoint cutaneous melanoma (CM).. Journal of Clinical Oncology. 42(16_suppl). 9507–9507. 10 indexed citations
3.
Lau, Peter K. H., S.J. Harris, Melissa Eastgate, et al.. (2023). CHARLI: A phase Ib/II trial of ipilimumab-nivolumab-denosumab or nivolumab-denosumab in patients with unresectable stage III and IV melanoma.. Journal of Clinical Oncology. 41(16_suppl). 9525–9525. 1 indexed citations
4.
Neven, Patrick, Erika Hamilton, Barbara Pistilli, et al.. (2023). 206P Capivasertib (C) + palbociclib (P) and fulvestrant (F) in patients (pts) with HR+/HER2- advanced breast cancer (ABC): Phase Ib data from CAPItello-292. ESMO Open. 8(1). 101395–101395. 2 indexed citations
5.
McDonnell, Alison M., et al.. (2022). Tissue-resident memory T cells in the era of (Neo) adjuvant melanoma management. Frontiers in Immunology. 13. 1048758–1048758. 11 indexed citations
6.
Parakh, Sagun, Daniel Roos, Amal Abou‐Hamden, et al.. (2022). Adult medulloblastoma in an Australian population. Journal of Clinical Neuroscience. 102. 65–70. 1 indexed citations
7.
Dimitriou, Florentia, Peter K. H. Lau, Prachi Bhave, et al.. (2021). Real-life data for first-line combination immune-checkpoint inhibition and targeted therapy in patients with melanoma brain metastases. European Journal of Cancer. 156. 149–163. 11 indexed citations
8.
Lau, Peter K. H., Carleen Cullinane, Susan Jackson, et al.. (2021). Enhancing Adoptive Cell Transfer with Combination BRAF-MEK and CDK4/6 Inhibitors in Melanoma. Cancers. 13(24). 6342–6342. 6 indexed citations
9.
Eckhardt, Bedrich L., Yuan Cao, Andrew Redfern, et al.. (2020). Activation of Canonical BMP4-SMAD7 Signaling Suppresses Breast Cancer Metastasis. Cancer Research. 80(6). 1304–1315. 51 indexed citations
10.
Lelliott, Emily J., Stefano Mangiola, Kelly M. Ramsbottom, et al.. (2020). Combined BRAF, MEK, and CDK4/6 Inhibition Depletes Intratumoral Immune-Potentiating Myeloid Populations in Melanoma. Cancer Immunology Research. 9(2). 136–146. 15 indexed citations
11.
Iravani, Amir, Medhat Osman, Alison M. Weppler, et al.. (2020). FDG PET/CT for tumoral and systemic immune response monitoring of advanced melanoma during first-line combination ipilimumab and nivolumab treatment. European Journal of Nuclear Medicine and Molecular Imaging. 47(12). 2776–2786. 49 indexed citations
12.
Oliver, Amanda J., Peter K. H. Lau, Sherene Loi, et al.. (2018). Tissue-Dependent Tumor Microenvironments and Their Impact on Immunotherapy Responses. Frontiers in Immunology. 9. 70–70. 118 indexed citations
13.
Yii, Anthony, Ser Hon Puah, Hui Fang Lim, et al.. (2018). A national audit of severe life-threatening asthma in Singapore. PA3957–PA3957. 3 indexed citations
14.
McMullen, Michelle, Peter K. H. Lau, Scott N. Taylor, et al.. (2017). Factors associated with psychological distress amongst outpatient chemotherapy patients: An analysis of depression, anxiety and stress using the DASS-21. Applied Nursing Research. 40. 45–50. 32 indexed citations
15.
Lau, Peter K. H., Paolo A. Ascierto, & Grant A. McArthur. (2016). Melanoma: the intersection of molecular targeted therapy and immune checkpoint inhibition. Current Opinion in Immunology. 39. 30–38. 19 indexed citations
16.
White, Alison M., Peter K. H. Lau, Andrew Redfern, & Max Bulsara. (2014). Capecitabine for ER-positive versus ER-negative breast cancer. Cochrane Database of Systematic Reviews. 1 indexed citations
17.
Lau, Peter K. H., Gabriel Lee, Michael Bynevelt, & Anna K. Nowak. (2014). Marked functional improvement after combined chemoradiotherapy for cervical spine glioblastoma causing quadriparesis in an adolescent. BMJ Case Reports. 2014. bcr2013202791–bcr2013202791. 6 indexed citations
18.
Lau, Peter K. H., et al.. (1988). Evaluation of a prescreening blood donor program for prevention of perinatal transfusion-acquired cytomegalovirus (CMV) infection. Journal of Perinatal Medicine. 16(2). 127–131. 7 indexed citations
19.
Judd, W. J., et al.. (1983). Studies on the blood of an MsHe/MSu proposita and her family. Transfusion. 23(5). 382–386. 5 indexed citations
20.
Lau, Peter K. H., et al.. (1980). Post‐transfusion purpura: An enigma of alloimmunization. American Journal of Hematology. 9(3). 331–336. 36 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Taner Babacan Breakdown of academic impact, for papers by Tian Tian Breakdown of academic impact, for papers by Lynn O’Donnell Breakdown of academic impact, for papers by Lisa Argnani Breakdown of academic impact, for papers by Shu‐Fang Hsu Schmitz Breakdown of academic impact, for papers by Émmanuelle Vigarios Breakdown of academic impact, for papers by M. Bauer Breakdown of academic impact, for papers by Xiaohan Shi Breakdown of academic impact, for papers by Theo van den Broek Breakdown of academic impact, for papers by Jacob Garcia
Rankless by CCL
2026